Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Cognition Therapeutics Inc
CGTX
Healthcare
Biotechnology
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the...
S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer’s disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (NDAQ:CGTX)
New Post
View:
Posts & Comments
Threaded Posts
(217)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Aug 25, 2025 5:54am
Buy buddy buy.
Otherwise FOMO for you fellas out there today anyway so good luck to all of you guys
(217)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Aug 13, 2025 8:15am
Using technical analysis for this stock.
It is signalling a big upswing for shareholders this morning so BUY it already or else FOMO
(27)
•••
ubiquitousman
X
Post by
ubiquitousman
on May 20, 2023 1:40pm
Ok, I will start, stock closed at $2.17 5-19-23-could be ..
interesting. Different take on AD. High risk play but I could make a case for this to be a $50-$100 stock in 24 months if they can prove efficacy in AD treatment. Stay tuned. Minute market cap of
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Featured News Links
Pinnacle Provides Progress Update for El Potrero Gold-Silver Project
Allied Critical Metals Announces Receipt of Environmental Permit for the Borralha Tungsten Project in Portugal
Sorrento Resources Announces Drilling Contract and Receives Permit to Drill Bottom Brook Project
Sranan Gold Reports 11 M Grading 7.33 g/t Gold Including 4 M at 14.59 g/t Gold
Global Currency Shifts Are Reshaping Commodities. Learn How. Secure Your Seat at VRIC 2026
Podcasts